SCHEMBL22358359

SCHEMBL22358359

CC(C)n1ncc2ccc(-c3noc(C4CCN(C(=O)c5ccc(Cl)cc5)CC4)n3)cc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
HTT P42858 4/20 0.54
TSHR P16473 3/20 0.54
GRM5 P41594 3/20 0.51
HSD11B1 P28845 1/20 0.50
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TUBB4A P04350 2/20 0.47
TUBB P07437 2/20 0.47
TUBA3C P0DPH7 2/20 0.47
TUBA1B P68363 2/20 0.47
TUBA4A P68366 2/20 0.47
TUBB4B P68371 2/20 0.47
TUBB3 Q13509 2/20 0.47
TUBB2A Q13885 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22358006 0.93 NPSR1 (0.47) LMNAHTTTSHRGRM5MAPT
SCHEMBL20116373 0.91 GRM5 (0.55) LMNAHTTTSHRGRM5MAPT
SCHEMBL22357915 0.91 SMN1; SMN2 (0.56) LMNAHTTTSHRGRM5HSD11B1
SCHEMBL22357882 0.91 SMN1; SMN2 (0.54) LMNAHTTTSHRHSD11B1SMN1; SMN2
SCHEMBL20116452 0.90 MAPT (0.44) LMNAHTTTSHRGRM5MAPT
SCHEMBL20116364 0.89 SMN1; SMN2 (0.44) LMNAHTTTSHRGRM5MAPT
SCHEMBL20116433 0.89 ALDH1A1 (0.51) LMNAHTTTSHRGRM5MAPT
SCHEMBL22357857 0.87 HSD11B1 (0.54) LMNAHTTTSHRGRM5HSD11B1
SCHEMBL20117167 0.87 SMN1; SMN2 (0.43) LMNAHTTTSHRGRM5MAPT
SCHEMBL20116401 0.87 SMN1; SMN2 (0.43) LMNAHTTTSHRGRM5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 LMNA 1966/4885HTT 6/4885TSHR 4679/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 LMNA 1966/4885HTT 6/4885TSHR 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.